Brivaracetam and rufinamide combination increased seizure threshold and improved neurobehavioral deficits in corneal kindling model of epilepsy
Animal Models and Experimental Medicine · 2025
DOI: 10.1002/ame2.12478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2025. Verfasst von Awais Sattar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Hauptthemen laut MEDLINE: Kindling, Neurologic, Pyrrolidinones, Seizures, Triazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Besides seizures, a myriad of overlapping neuropsychiatric and cognitive comorbidities occur in patients with epilepsy, which further debilitates their quality of life. This study provides an in‐depth characterization of the impact of brivaracetam and rufinamide individually and in combination at 10 and 20 mg/kg doses, respectively, on corneal kindling‐induced generalized seizures and behavioral alterations. Furthermore, observed convulsive frequency and behavioral changes were correlated to post‐kindling‐induced changes in the activity of markers of oxidative stress.
Methods
Adult C57BL/6 mice were kindled via twice‐daily transcorneal 50‐Hz electrical stimulations (3 mA) for 3 s for 12 days until animals reached a fully kindled state. After the kindling procedure, animals were tested using a set of behavioral tests, and neurochemical alterations were assessed.
Results
Corneal‐kindled animals exhibited intense generalized convulsions, altered behavioral phenotypes typified by positive symptoms (hyperlocomotion), negative symptoms (anxiety and anhedonia), and deficits in semantic and working memory. BRV 10 + RFM 20 dual regime increased convulsive threshold and propensity toward the start of stage 4–5 seizures and improved phenotypical deficits, that is, anxiety, depression, and memory impairments. Moreover, this combination therapy mitigated kindling‐induced redox impairments as evidenced by reduced malondialdehyde and acetylcholinesterase levels and increased glutathione antioxidant activity in the brain of animals subjected to repetitive brain insult.
Conclusion
Based on our outcomes, this dual therapy provides supporting evidence in alleviating epilepsy‐induced neurobehavioral comorbidities and changes in redox homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
- Institut pour l'Avancée des Biosciences, Centre de Recherche UGA/INSERM U1209/CNRS 5309, Université Grenoble Alpes, Saint Martin d'Hères, France.
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
ORCID-Profile: Waseem Ashraf, Imran Imran
Zitieren
APA
Sattar, A., Rehman, Z., Murtaza, H., Ashraf, W., Ahmad, T., Alqahtani, F., & Imran, I. (2025). Brivaracetam and rufinamide combination increased seizure threshold and improved neurobehavioral deficits in corneal kindling model of epilepsy. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.12478
Vancouver
Sattar A, Rehman Z, Murtaza H, Ashraf W, Ahmad T, Alqahtani F, et al. Brivaracetam and rufinamide combination increased seizure threshold and improved neurobehavioral deficits in corneal kindling model of epilepsy. Animal Models and Experimental Medicine. 2025. doi:10.1002/ame2.12478
BibTeX
@article{Sattar2025,
author = {Sattar, Awais and Rehman, Zohabia and Murtaza, Hammad and Ashraf, Waseem and Ahmad, Tanveer and Alqahtani, Faleh and Imran, Imran},
title = {Brivaracetam and rufinamide combination increased seizure threshold and improved neurobehavioral deficits in corneal kindling model of epilepsy},
journal = {Animal Models and Experimental Medicine},
year = {2025},
doi = {10.1002/ame2.12478}
}
EUVIMED